Drug Profile
Research programme: asthma therapy - Sirna Therapeutics
Alternative Names: Asthma therapy research programme - Sirna TherapeuticsLatest Information Update: 03 Jan 2007
Price :
$50
*
At a glance
- Originator Sirna Therapeutics
- Class RNA
- Mechanism of Action Cytokine modulators; RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
- 10 Jan 2005 Preclinical trials in Asthma in USA (Inhalation)